Anti-β1-adrenergic receptor autoantibody (Anti-β1AR autoantibody)

Anti-β1-adrenergic receptor autoantibodies are autoantibodies (primarily of the IgG class and its subclasses, such as IgG3) that bind to conformational epitopes on the β1-adrenergic receptor, a G protein-coupled receptor centrally involved in cardiac function[1][2][3][5]. These autoantibodies can act as agonists or antagonists, modulating receptor activity and downstream signaling pathways (cAMP/PKA and β-arrestin), often leading to pathogenic effects such as cardiomyocyte apoptosis, receptor desensitization, and persistent calcium influx. They have been strongly linked to dilated cardiomyopathy, chronic heart failure, and other cardiac pathologies. Their pathogenic role is underscored by both their presence in patient populations and the observed clinical improvement following their selective removal. The IgG subclass significantly influences their effect on receptor signaling and response to medications. The detection of these autoantibodies serves as a biomarker for disease presence, prognosis, and patient selection for immunoadsorption therapy or specific β-blocker regimens[1][2][4][5].

Other names

β1-adrenergic receptor autoantibodyβ1AR-AAbanti-β1AR antibodyanti-β1-adrenergic receptor antibody

Acts as a functional agonist or antagonist to the β1-adrenergic receptor, depending on the IgG subclass and disease context. Modulates β1-adrenergic receptor conformation, affecting G-protein and β-arrestin signaling. Biases β-blocker activity toward G-protein signaling or disrupts desensitization/internalization of the receptor[1][2][5].